According to Anne Webster, NP, of UnityPoint Health, many patients with diabetes saw insulin prices soar last fall as several drug companies withdrew from the federal 340B program.

According to Anne Webster, NP, of UnityPoint Health, many patients with diabetes saw insulin prices soar last fall as several drug companies withdrew from the federal 340B program.

Webster said she had been forced to prescribe less effective insulin options in the past few months and saw patients begin to ration their medication. Webster said she has not only compromised her physical health in recent months, but has seen patients struggling with their mental and financial well-being, and sees no end in sight. The only solution, she said, is for Xavier Becerra, JD, director of health and human services, to enforce federal guidelines to ensure affordable access to medicines.

Read More Now